Roche culls cough candidate, pivots KRAS program after revaluing entire pipeline

Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate disappointed in phase 2, disclosed the setback as part of a wider pullback from prospects that fell short of the bar for further development.